MARKER THERAPEUTICS INC
MRKRNASDAQTrading Snapshot
- Day Range
- $1.08 – $1.12
- 52-Week Range
- $0.84 – $2.46
- Volume
- $4.78B
- Avg Volume
- $4.50B
- Shares Outstanding
- 16.7M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $809,080
- P/E Ratio
- —
- P/S Ratio
- 5.5x
- EPS (TTM)
- $-0.90
- Dividend Yield
- —
- Dilution (1yr)
- +68.2%
Why Investors Own MRKR
- ✓High-growth profile — revenue up +3.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 62% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MARKER THERAPEUTICS INC
MRKR
StockOtter · stockotter.spaceAbout MARKER THERAPEUTICS INC
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
